Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hereditary Hemorrhagic Telangiectasia (HHT): early-phase trial registry
1 of 4 indexed Hereditary Hemorrhagic Telangiectasia (HHT) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hereditary Hemorrhagic Telangiectasia (HHT): 4 US clinical trials tracked, 1 recruiting.
Hereditary Hemorrhagic Telangiectasia (HHT) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Vaderis Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition hereditary-hemorrhagic-telangiectasia-hht
OPEN 1 | RECR 25% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Hereditary Hemorrhagic Telangiectasia (HHT) lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hereditary Hemorrhagic Telangiectasia (HHT) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hereditary Hemorrhagic Telangiectasia (HHT) is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Terremoto Biosciences
NCT07255846
Assess Safety and Efficacy of VAD044 in HHT Patients
Vaderis Therapeutics
NCT05406362
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
Massachusetts General Hospital
NCT07018401
Graded TTCE for Post-Embolization PAVM Monitoring
University of Pennsylvania
NCT02936349
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hereditary Hemorrhagic Telangiectasia (HHT) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hereditary Hemorrhagic Telangiectasia (HHT) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hereditary Hemorrhagic Telangiectasia (HHT) page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hereditary Hemorrhagic Telangiectasia (HHT) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vaderis Therapeutics sponsors the most Hereditary Hemorrhagic Telangiectasia (HHT) trials on record, review their full trial history before evaluating a specific study. See Vaderis Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hereditary Hemorrhagic Telangiectasia (HHT) condition card totals 4 registered trials; most-linked intervention Transthoracic Contrast Echocardiogram; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.